Evidence map›Paper›PMID 38763945›Full record

ArticleSports medicine - open2024

Doping Prevalence among U.S. Elite Athletes Subject to Drug Testing under the World Anti-Doping Code.

Ann Kearns Davoren, Kelly Rulison, Jeff Milroy, Pauline Grist, Matthew Fedoruk, Laura Lewis, David Wyrick

Abstract read
In one paragraph

Article in Sports medicine - open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Erythropoiesis-Targeted Doping in Sports: From Improved Oxygen Transport to Cardiovascular Risk.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ann Kearns DavorenPrevention Strategies, Greensboro, NC, USA. akdavoren@preventionstrategies.com.ORCID http://orcid.org/0000-0001-9367-4415
Kelly RulisonPrevention Strategies, Greensboro, NC, USA.
Jeff MilroyThe University of North Carolina Greensboro, Greensboro, NC, USA.
Pauline GristThe University of North Carolina Greensboro, Greensboro, NC, USA.
Matthew FedorukU.S. Anti-Doping Agency (USADA), Colorado Springs, CO, USA.
Laura LewisU.S. Anti-Doping Agency (USADA), Colorado Springs, CO, USA.
David WyrickPrevention Strategies, Greensboro, NC, USA.

Funding

United States Anti Doping Agency United States Anti Doping Agency
6 · The paper itself

Abstract

backgroundDetermining the prevalence of doping within an elite athlete population is challenging due to the extreme sensitivity of the topic; however, understanding true doping prevalence is important when designing anti-doping programs and measuring their effectiveness. The objective of this study was to estimate the prevalence of doping among Olympic, Paralympic, World, and National-level competitive athletes in the United States subject to the World Anti-Doping Code. All athletes who were subject to the U.S. Anti-Doping Agency's Protocol for Olympic and Paralympic Movement Testing, a World Anti-Doping Code ("Code")-compliant anti-doping program, were invited to complete a web-delivered survey. Using a direct questioning approach, the survey items asked athletes whether they had used each specific category of banned substance / method on the World Anti-Doping Agency's Prohibited List. Multiple strategies to encourage honest reporting (e.g., protecting anonymity by collecting minimal demographic information; using an outside organization to administer the survey) and to detect inconsistent responses were used.

resultsDepending on the method of calculation, 6.5-9.2% of the 1,398 respondents reported using one or more prohibited substances or methods in the 12 months prior to survey administration. Specific doping prevalence rates for each individual substance / method categories ranged from 0.1% (for both diuretics / masking agents and stem cell / gene editing) to 4.2% for in-competition use of cannabinoids.

conclusionDetermining the prevalence of doping within different athlete populations is critical so that sport governing bodies can evaluate their anti-doping efforts and better tailor their programming. By measuring doping prevalence of specific categories of substances and methods, rather than just the overall prevalence of doping, this study also highlights where sport governing bodies should focus their future educational and detection efforts.

Indexed as

AthletesDoping prevalencePerformance enhancing drugs

Identifiers

PMID38763945
PMCPMC11102888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.